The plant-based coronavirus vaccine tested in Argentina received its first authorization from Canada and will be applied to adults aged 18 to 64 years. Its effectiveness in clinical trials is 71%.
This is the first vaccination carried out with a plant protein against Covid-19, which has approval from an official body. This could facilitate the production of this type of drug in the fight against the pandemic.
Libreta AUH ANSES: cómo dar el alta a la credencial de vacunación contra el COVID, ¿qué se pide para cobrar el Complemento?
The benefits were developed through Medicago pharmacy and the use of the GlaxoSmithKline (GSK) adjuvant to increase its effectiveness. The studies reported the participation of more than 24,000 volunteers in the phase 3 trials, with Argentina being the country with the maximum 50% of participants. .
Según el informe de Medicago, la vacuna utiliza una tecnología que genera partículas similares al virus las cuales son capaces de imitar su estructura sin contener material genético del mismo, algo que especialmente útil cuando se busca combatir la particular forma que tiene el coronavirus,
In studies carried out in December, it was found that the effectiveness of the vaccine is lower than that of the Delta variant (75. 3%). However, there is no certification for the new Omicron variant, which was not circulating at the time of the study.
Medicago CEO Takashi Naga called the approval “a significant blow to Canada in the fight against the pandemic” and said the company “in the process of producing a dose to go live with the governor’s mandate. “
“This is the first legal covid-19 vaccine developed through a Canadian-based corporation and the first to use plant-based protein technology,” the Government of Canada announced in a press release.
Xi Jinping with Putin and negotiated with Ukraine
Otro de los datos compartidos en el informe de eficacia de la vacuna se centra en la participación de voluntarios argentinos en las pruebas de fase 3 de la misma, los cuales comprenden aproximadamente el 50% de los voluntarios totales (unas 12 mil personas).
The same was done in the five centers, and the largest number of participants was obtained in the central military hospital; before the Pfizer vaccine clinical trial runs out.